More recently, lorlatinib has been approved by FDA and EMA in first-line in NSCLC patients: the decision was based on findings from the phase 3 CROWN trial that compared lorlatinib to crizotinib in patients with ALK-translocated advanced NSCLC, not previously treated. This evidence concerns the gene ALK and non-small cell lung carcinoma.